Compass Therapeutics (CMPX) Income from Continuing Operations (2018 - 2026)
Compass Therapeutics recorded quarterly Income from Continuing Operations of 20299000.0 in Q1 2026, down 12.83% quarter-over-quarter from 17990000.0 in Q4 2025, and down 22.04% year-over-year from 26037885.94 in Q1 2025.
Compass Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 20299000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 22.04% year-over-year to 20299000.0; the TTM figure through Mar 2026 stood at 75172000.0 (down 28.45% YoY), while the FY2025 annual figure was 72839000.0, down 28.63% from the prior year.
- Income from Continuing Operations came in at 20299000.0 for Q1 2026 at Compass Therapeutics, down from 17990000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7162000.0 in Q1 2022 to a low of 21066000.0 in Q2 2025.
- A 5-year average of 13305882.35 and a median of 12239000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 100.42% in 2022 and increased 16.79% in 2023, its largest moves.
- Compass Therapeutics' Income from Continuing Operations stood at 11594000.0 in 2022, then slipped by 15.71% to 13415000.0 in 2023, then fell by 23.55% to 16574000.0 in 2024, then fell by 8.54% to 17990000.0 in 2025, then fell by 12.83% to 20299000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 20299000.0, 17990000.0, and 15817000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -20.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.30 Mn |
| Dec 31, 2025 | -17.99 Mn |
| Sep 30, 2025 | -15.82 Mn |
| Jun 30, 2025 | -21.07 Mn |
| Mar 31, 2025 | -16.63 Mn |
| Dec 31, 2024 | -16.57 Mn |
| Sep 30, 2024 | -12.24 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -10.79 Mn |
| Dec 31, 2023 | -13.42 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -7.84 Mn |
| Dec 31, 2022 | -11.59 Mn |
| Sep 30, 2022 | -11.98 Mn |
| Jun 30, 2022 | -8.49 Mn |
| Mar 31, 2022 | -7.16 Mn |
| Dec 31, 2021 | -12.98 Mn |
| Sep 30, 2021 | -5.98 Mn |
| Mar 31, 2021 | -7.42 Mn |
| Sep 30, 2020 | -9.15 Mn |
| Jun 30, 2020 | -5.56 Mn |
| Mar 31, 2020 | -6.40 Mn |
| Dec 31, 2019 | -11,682.00 |
| Sep 30, 2019 | -8.55 Mn |
| Jun 30, 2019 | -8.81 Mn |
| Dec 31, 2018 | -10,142.00 |
| Sep 30, 2018 | -8,556.00 |
| Jun 30, 2018 | -8,474.00 |